Alzheimer's Pharmacology (Hoyt)
5 Questions
| Total Attempts: 380
Settings
A person suffering from Alzheimer’s disease calls for specialized care and treatment. As a medical practitioner how well do you understand the disease and drugs prescribed to the patient? Take up the simple quiz on Alzheimer’s pharmacology and let the results speak for themselves. All the best as you tackle it!
Questions and Answers
- 1.The pathogenesis of AD is associated with loss of brain tissue and neurons in which areas of the brain? (Check all that apply)
- A.
Amygdala
- B.
Basal forebrain
- C.
Frontal cortex
- D.
Hippocampus
- E.
Temporal cortex
- 2.Which of the following enzymes are important in choline signaling that is considerably reduced in the development of AD? (Check TWO that apply)
- A.
Acetylcholinesterase
- B.
Butrylcholinesterase
- C.
Choline acetyltransferase
- D.
Nicotinic acetylcholine receptor
- 3.Rivastigmine (Exelon), an cholinesterase inhibitor used in AD, has a greater potency for one of the two isoforms of AChE in the brain because with AD progression, there is preferential loss of one of the isoforms and thus the drug targets the one that IS remaining. Which isoform does rivastigmine (Exelon) target?
- A.
G1 (monomer)
- B.
G4 (tetramer)
- 4.Which of the cholinesterase inhibitors used in AD is also a positive allosteric modulator of nicotinic acetylcholine receptors to synergistically increase the [acetylcholine] in the synapse?
- A.
Tacrine (Cognex)
- B.
Donepezil (Aricept)
- C.
Galantamine (Razadyne)
- D.
Memantine (Namenda)
- E.
Rivastigmine (Exelon)
- 5.Memantine (Namenda) is a ______ antagonist at the NMDA receptor which is a channel of ____ and ____ ions.
- A.
Uncompetitive; sodium; potassium
- B.
Uncompetitive; sodium; calcium
- C.
Competitive; potassium; magnesium
- D.
Competitive; magnesium; calcium
Back to top